The Effects of Implementing a Mobile Health–Technology Supported Pathway on Atrial Fibrillation–Related Adverse Events Among Patients With Multimorbidity
Yuan Yao,Yutao Guo,Gregory Y. H. Lip,Yutao Guo,Gregory Y H Lip,Deirdre A. Lane,Yundai Chen,Liming Wang,Jens Eckstein,G Neil Thomas,Tong Liu,Mei Feng,Xuejun Liu,Xiaoming Li,Zhaoliang Shan,Xiangming Shi,Wei Zhang,Yunli Xing,Jing Wen,Fan Wu,Sitong Yang,Xiaoqing Jin,Bo Yang,Xiaojuan Bai,Yuting Jiang,Yangxia Liu,Yingying Song,Zhongju Tan,Li Yang,Tianzhu Luan,Chunfeng Niu,Lili Zhang,Shuyan Li,Zulu Wang,Bing Xv,Liming Liu,Yuanzhe Jin,Yunlong Xia,Xiaohong Chen,Fang Wu,Lina Zhong,Yihong Sun,Shujie Jia,Jing Li,Nan Li,Shijun Li,Huixia Liu,Rong Li,Fan Liu,Qingfeng Ge,Tianyun Guan,Yuan Wen,Xin Li,Yan Ren,Xiaoping Chen,Ronghua Chen,Yun Shi,Yulan Zhao,Haili Shi,Yujie Zhao,Quanchun Wang,Weidong Sun,Lin Wei,Esther Chan,Guangliang Shan,Chen Yao,Wei Zong,Dandi Chen,Xiang Han,Anding Xu,Xiaohan Fan,Ziqiang Yu,Xiang Gu,Fulin Ge,
DOI: https://doi.org/10.1001/jamanetworkopen.2021.40071
2021-12-21
JAMA Network Open
Abstract:Importance: The Mobile Health Technology for Improved Screening and Optimized Integrated Care in Atrial Fibrillation (mAFA-II) trial is a prospective cluster randomized trial that found a significant reduction in the composite clinical outcome of stroke or thromboembolism, all-cause death, and rehospitalization among patients with atrial fibrillation (AF) who used a mobile health (mHealth) technology that implemented the Atrial Fibrillation Better Care (ABC) pathway (ie, A, anticoagulation/avoid stroke; B, better symptom control; and C, cardiovascular disease and comorbidity management) compared with those receiving usual care. Multimorbidity (defined as ≥2 chronic long-term conditions) is common in older patients with AF, but the impact of integrated or holistic care (based on the ABC pathway) on clinical outcomes in this population is uncertain.Objective: To evaluate whether implementation of the integrated ABC pathway, supported by mHealth technology, would reduce AF-related adverse events in patients with multimorbidity.Design, Setting, and Participants: This prespecified ancillary analysis of data from the extended follow-up of the mAFA II trial was conducted between June 2018 and April 2021. Adult patients with AF were included in the analysis if they had at least 2 comorbidities. Participants were enrolled across 40 centers in China.Intervention: Integrated care supported by mHealth technology (mAFA intervention) vs usual care.Main Outcomes and Measures: The main outcome was the composite outcome of stroke or thromboembolism, all-cause death, and rehospitalization. Cox proportional hazard modeling was performed for adverse outcomes after adjusting for cluster effect and baseline risk factors.Results: Of 1890 patients, 833 (mean [SD] age, 72.0 [12.0] years; 278 [33.4%] women) with multimorbidity were allocated to the intervention group (ABC pathway), with a mean (SD) follow-up of 419 (257) days, and 1057 patients (mean [SD] age, 72.8 [13.0] years; 443 [41.9%] women) with multimorbidity were allocated to usual care, with a mean (SD) follow-up of 457 (154) days. Compared with usual care, the composite outcome of stroke or thromboembolism, all-cause death, and rehospitalization was significantly reduced in the intervention group (hazard ratio [HR], 0.37; 95% CI, 0.26-0.53; P < .001), as were rehospitalizations alone (HR, 0.42; 95% CI, 0.27-0.64; P < .001). For the C criterion of the ABC pathway, rates of acute coronary syndrome, heart failure, and uncontrolled blood pressure during follow-up were lower in the intervention group than the usual care group (27 patients [3.2%] vs 145 patients [13.7%]; HR, 0.29; 95% CI, 0.19-0.45; P < .001). Subgroup analyses by age, prior stroke, and sex demonstrated consistently lower HRs for the primary composite outcome and rehospitalization for patients with AF allocated to the intervention group compared with patients receiving usual care.Conclusions and Relevance: In this study, mHealth technology-based integrated care that facilitated the implementation of the ABC pathway reduced meaningful clinical adverse events in older patients with AF and multimorbidity vs usual care.Trial Registration: WHO International Clinical Trials Registry Platform (ICTRP) Registration number: ChiCTR-OOC-17014138.
medicine, general & internal